Authors:
Carty, E
Rampton, DS
Schneider, H
Rutgeerts, P
Wright, JP
Citation: E. Carty et al., Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease, ALIM PHARM, 15(9), 2001, pp. 1323-1329
Citation: E. Carty et al., Inhibition of platelet activation by 5-aminosalicylic acid in inflammatorybowel disease, ALIM PHARM, 14(9), 2000, pp. 1169-1179
Authors:
Carty, E
Macey, M
Mccartney, SA
Rampton, DS
Citation: E. Carty et al., Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease, ALIM PHARM, 14(6), 2000, pp. 807-817
Authors:
Carty, E
De Brabander, M
Feakins, RM
Rampton, DS
Citation: E. Carty et al., Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper, GUT, 46(4), 2000, pp. 487-492
Authors:
Macey, MG
Carty, E
Webb, L
Chapman, ES
Zelmanovic, D
Okrongly, D
Rampton, DS
Newland, AC
Citation: Mg. Macey et al., Use of mean platelet component to measure platelet activation on the ADVIA120 haematology system, CYTOMETRY, 38(5), 1999, pp. 250-255
Authors:
Zhang, Z
Naughton, DP
Carty, E
Rampton, DS
Citation: Z. Zhang et al., Excess nitric oxide in ulcerative colitis may be generated by nitric oxidesynthase independent pathways, GUT, 44(3), 1999, pp. 441-441